Skip to main content
Swing Capital

Pfizer Ltd

NSE: PFIZER BSE: 500680Pharma

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1] It is the 3rd largest multinational pharmaceutical company in India.[2]

₹4,865
52W: ₹4405 — ₹5993
PE 29.3 · Book ₹919 · +429% vs book
Market Cap₹22,256 Cr
Stock P/E29.3Price to Earnings
ROCE24.2%Return on Capital
ROE18%Return on Equity
Div. Yield0.72%Face Value ₹10

Strengths

  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 58.3%

Weaknesses

  • −The company has delivered a poor sales growth of 2.39% over past five years.

Shareholding Pattern

Promoters63.92%
FIIs2.81%
DIIs16.89%
Public16.36%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters63.92%63.92%63.92%63.92%63.92%63.92%63.92%63.92%
FIIs3.22%3.54%▲0.32.74%▼0.82.18%▼0.62.4%▲0.22.6%▲0.22.71%▲0.12.81%▲0.1
DIIs15.83%16.03%▲0.216.8%▲0.817.1%▲0.317.23%▲0.117.11%▼0.117.05%▼0.116.89%▼0.2
Public17%16.5%▼0.516.54%▲0.016.79%▲0.316.45%▼0.316.37%▼0.116.32%▼0.116.36%▲0.0

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales540547563589538592603642645629
Expenses387357385399392364393412417393
Operating Profit153189177189146228210230228236
OPM %28%35%32%32%27%38%35%36%35%38%
Net Profit130179151158128331192189142200
EPS ₹28.4139.132.9434.6127.8972.3441.9141.323143.68

AI Insights

Revenue Trend

Mar 2026 revenue at ₹2,520Cr, up 10.5% YoY. OPM at 36%.

Debt Position

Borrowings at ₹70Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.

Capex Cycle

CWIP at ₹20Cr (3% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 16.89% (+2.00pp change). FIIs: 2.81% (+0.00pp change). Promoters hold 63.92%.

Margin & Efficiency

ROCE improving from 24% (Mar 2015) to 24% (Mar 2026). Working capital days: 9.

Valuation

PE 29.3x with 24.2% ROCE. Price is 429% above book value of ₹919. Dividend yield: 0.72%.

Recent Announcements